z-logo
open-access-imgOpen Access
Toxic epidermal necrolysis in a patient on atorvastatin therapy expressing human leukocyte antigen alleles
Author(s) -
Meina Lv,
Shaojun Jiang,
Jinglan Fu,
Yuxin Liu,
Siheng Lian,
Jinhua Zhang
Publication year - 2021
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000024392
Subject(s) - medicine , toxic epidermal necrolysis , rash , atorvastatin , adverse effect , allele , human leukocyte antigen , dermatology , skin patch , gastroenterology , immunology , antigen , biochemistry , chemistry , gene
Rationale: Toxic epidermal necrolysis (TEN) is a rare, severe mucosal response of the skin associated with a high mortality rate. TEN is most commonly caused by drugs, and is characterized by extensive skin epidermal exfoliation. Patient concerns: A 68-year-old woman presented with a rash that had persisted for four days. The patient who had undergone a mitral valve replacement 1 month prior and was taking atorvastatin at the time of admission. Diagnoses: The patient exhibited more than 30% exfoliation surfaces and the severe drug eruption was considered to be TEN. According to human leukocyte antigen (HLA) allele detection and ALDEN score, HLA alleles which found in this case report may be an cause of TEN induced by atorvastatin. Interventions: All drugs used prior to admission were discontinued and the patient was given antiallergic drugs. Outcomes: After 3 weeks following Antiallergic treatment, the rash on patient's calf had subsided, the edema was relieved, and the patient was no longer experiencing pain. After 60 days following discharge, the patient's skin has regrown. Lessons: This is the first report describing the induction of TEN by atorvastatin in a HLA alleles carrier. For HLA alleles carrier, atorvastatin may need to be used with caution to avoid TEN. Future systematic research is also required to confirm this finding and avoid similar serious skin adverse reactions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here